Serum Zinc, Peptic Ulcer Disease and H. Pylori Infection
1 other identifier
observational
75
0 countries
N/A
Brief Summary
Fifty consecutive patients with symptoms suggestive of peptic ulcer disease were included. All underwent complete clinical evaluation, laboratory investigations, upper gastrointestinal endoscopy and rapid urease test. Measurement of serum zinc level was done for all the included patients in addition to twenty five age and sex matched healthy control subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2013
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedFirst Submitted
Initial submission to the registry
March 17, 2016
CompletedFirst Posted
Study publicly available on registry
March 22, 2016
CompletedMarch 22, 2016
March 1, 2016
1.8 years
March 17, 2016
March 21, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Detection of positive upper GIT endoscopic findings
upon endoscopy
Study Arms (2)
Case Group
Control Group
Interventions
Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
Eligibility Criteria
patients with symptoms suggestive of peptic ulcer disease like epigastric pain, dyspepsia, heartburn who were candidates for upper gastrointestinal endoscopy.
You may qualify if:
- Symptoms suggestive of peptic ulcer disease like epigastric pain, dyspepsia, heartburn
You may not qualify if:
- Patients who received zinc supplementation, proton pump inhibitors (PPI), non-steroidal anti-inflammatory drugs (NSAIDs)
- Those presented with hematemesis or melena
- Those with chronic liver disease, renal failure, malabsorption or previous gastric surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
March 17, 2016
First Posted
March 22, 2016
Study Start
October 1, 2013
Primary Completion
August 1, 2015
Study Completion
August 1, 2015
Last Updated
March 22, 2016
Record last verified: 2016-03